Skip to main content

Select Drug Profiles

FDA Approvals, Payers' Guide
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Competition Heats Up in Rheumatoid Arthritis and Other Autoimmune Conditions
Gary Branning, MBA
Read More
FDA Approvals, Payers' Guide
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
Clinical Pathways and the Oncology Medical Home: First Steps to Value-Based Patient Care
Chase Doyle
Read More
Page 116 of 244
Results 1151 - 1160 of 2434